Commercial License. For each Collaboration Program, Poseida hereby grants to Roche, effective upon Collaboration Research Program Designation of the applicable Collaboration Program (and after the HSR Clearance Date for such Collaboration Research Program Designation if Roche determines an HSR Filing is required with respect to such Collaboration Research Program Designation), an exclusive, non-transferable (except as permitted pursuant to [Section 17.3]), worldwide and royalty-bearing license, including the right to sublicense through multiple tiers (in accordance with [Section 6.8]), under the Poseida Background IP and Poseida’s interest in Joint IP, in each case, to make, use, offer for sale, sell, import, and otherwise fully exploit in the Field the Collaboration Products from such Collaboration Program.

License. Commencing on the later of the Rent Commencement Date or the date that any Submarket Amenities are made available for use by Tenant, and so long as the applicable Submarket Project and the Project continue to be owned by affiliates of ARE, Tenant shall have the non-exclusive right to the use of the available Submarket Amenities in common with other Users pursuant to the terms of this Section 40. To the extent that the Submarket Amenities include a fitness center, 247 fitness center passes shall be issued to Tenant for employees of Tenant.

Commercial License. Such particular Pre-IND Collaboration Candidate will be deemed a Licensed Collaboration Candidate, and the Commercial License granted to Janssen under [Section 5.1.2] shall apply to such Licensed Collaboration Candidate and the corresponding Licensed Products.

License. If any part of the Services, Deliverables, or rights assigned to FivePrime hereunder cannot be reasonably and fully made, used, reproduced, distributed or otherwise exploited without using or violating technology or intellectual property rights owned by Consultant (or any person involved in performance of the Services) and not assigned hereunder, Consultant hereby grants FivePrime and its successors a perpetual, irrevocable, worldwide, royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such technology and intellectual property rights in support of FivePrime’s exercise or exploitation of the Services, Deliverables, and any assigned rights (including any modifications, improvements, and derivatives of any of them). If Consultant has any rights, including “artist’s rights” or “moral rights,” in the Deliverables, Innovations or IP Rights that cannot be assigned, Consultant hereby unconditionally and irrevocably grants to FivePrime an exclusive (even as to Consultant), worldwide, fully-paid and royalty-free, irrevocable, perpetual license, with rights to sublicense through multiple tiers of sublicensees, to use, reproduce, distribute, create derivative works of, publicly perform and publicly display the Deliverables, Innovations and IP Rights, in any medium or format, whether now known or later developed. In the event that Consultant has any rights in the Deliverables, Innovations or IP Rights that cannot be assigned or licensed, Consultant unconditionally and irrevocably waives the enforcement of such rights, and all claims and causes of action of any kind, against FivePrime or any third party. For clarity, the Deliverables, Innovations, and IP Rights constitute Confidential Information of FivePrime.

License. Company may distribute Products together with all required Product Components, as specified in the Additional Terms and Guides, to Qualified Customers located in the Territory, and may also distribute Products to Authorized Subcontractors s worldwide (subject to any additional terms applicable to worldwide distribution in the Guides). Except as expressly allowed in the Agreement, Company will not distribute, sublicense, lease, rent, loan or otherwise transfer the Authenticity Tags, APM, or the Product to any third party.

License. For the sole purpose of enabling Agent to exercise its rights and remedies as to the Collateral under this Agreement and Applicable Law, Agent is hereby granted an irrevocable, non-exclusive license or other right to use, license or sub-license (without payment of royalty or other compensation to any Person) any Intellectual Property of Obligors, computer hardware and software, brochures, customer lists, promotional and advertising materials, labels, packaging materials and other Property, in advertising for sale, marketing, selling, collecting, completing manufacture of, or otherwise exercising any rights or remedies with respect to, any Collateral. For clarity, this license is effective only while an Event of Default exists and is irrevocable until the termination of this Agreement. Each Obligor’s rights and interests under Intellectual Property shall inure to Agent’s benefit.

Commercial License Option. Poseida hereby grants to Roche a non- exclusive option, exercisable at any time during the R&D License Term, for the non-exclusive, commercial license under the Licensed Technologies set forth in [Section 6.6.4(b)] (the “Commercial License Option”). Roche may exercise the Commercial License Option by providing written notice to Poseida of its election during the R&D License Term (the “Commercial License Option Exercise”). If Roche provides such notice, Roche shall pay the Commercial License Fee to Poseida as provided in [Section 8.5.2].

#[[Carnegie Mellon:Organization]] hereby grants to Licensee the option (“Option”) to negotiate an exclusive license from [[Carnegie Mellon:Organization]] to manufacture, use, sell, lease or otherwise dispose of products and/or services based on, in whole or in part, the technology and intellectual property comprised in the [[Carnegie Mellon:Organization]] Materials and to practice under the Patent for exosome and cellular therapeutic applications.

Commercial License Fee. If Roche exercises the Commercial License Option set forth in [Section 6.6.4(a)] with respect to Off-The-Shelf TCR-Expressing Cell Therapies Directed To a particular Licensed Target (which shall become a Designated Licensed Target as a result of such exercise) and Personalized TCR-Expressing Cell Therapies, Roche shall pay Poseida a one- time, non-creditable, non-refundable commercial license fee in the amount of ​ (“Commercial License Fee”). Poseida shall invoice Roche for the Commercial License Fee after written notice from Roche of its election to exercise the Commercial License Option pursuant to [Section 6.6.4(a)], and Roche will pay Poseida within ​ of receipt of an undisputed invoice from Poseida with respect thereto.

License. Commencing on the Second Expansion Space Rent Commencement Date, and so long as The Alexandria, the Campus Point Project and the Project continue to be owned by affiliates of ARE, Tenant shall have the non-exclusive right to the use of the available Alexandria Regional Amenities in common with other Users pursuant to the terms of this Section 10. Notwithstanding the foregoing, commencing on the Second Expansion Space Commencement Date, Tenant shall only be entitled to 2.5 passes to the fitness center located at The Alexandria per 1,000 rentable square feet of the Second Expansion Space for use by employees of Tenant employed at the Premises (Tenant shall be entitled to an additional 2.5 passes to the fitness center per 1,000 rentable square feet of the Original Premises as of April 16, 2024 and an additional 2.5 passes to the fitness center per 1,000 rentable square feet of the Expansion Premises as of January 1, 2026, if applicable). If any employee of Tenant to whom a fitness center pass has been issued ceases to be an employee of Tenant at the Premises or any employee to whom an access card (which does not include a fitness center pass) has been issued ceases to be an employee of Tenant at the Premises, Tenant shall immediately upon such employee’s change in status collect such employee’s pass or access card, as applicable, and deliver it to Landlord along with written notice of such employee’s change in status.